“Johnson & Johnson is engaged in the manufacture and sale of a broad range of products in the health care field in many countries of the world. The company's worldwide business is divided into three segments: Consumer; Pharmaceutical; and Professional.”
Dividend Yield: 2.6%
Dividend Yield 5yr Avg: 1.9 %
ROE levels of above 21% for the past 10 years
Current P/E– 18
Projected 2007 P/E –16
Projected 2008 P/E – 15
4 Star rating from S&P - $74 one year target
Argus rates it a buy with a $76 one year target
-44 years of consistent dividend growth.
-Dividends issued to shareowners every quarter since 1944.
-Dividend raised each year for 44 consecutive years.
-Sales have increased each year for 73 consecutive years.
-Double digit Earnings increases for 21 consecutive years.
-44% of sales outside of North America
THESIS: JNJ sells hundreds of brand name products in the health care space. As the population ages they will increasingly be using more health care products and devices made be JNJ. I am very bullish on the long term prospects of JNJ and currently have close to 6% of my portfolio invested with them. I would continue to accumulate as both JNJ and the American dollar dips.